From the trastuzumab era to new target therapies: beyond revolution

被引：10

作者：

Barni, S. ^{[1
]}

Petrelli, F. ^{[1
]}

Cabiddiu, M. ^{[1
]}

Cazzaniga, M. E. ^{[1
]}

Cremonesi, M. ^{[1
]}

机构：

[1] Treviglio Hosp, Div Med Oncol, Bergamo, Italy

来源：

ANNALS OF ONCOLOGY | 2007年 / 18卷

关键词：

D O I：

10.1093/annonc/mdm214

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1 / 4

页数：4

共 17 条

[1]

[Anonymous], 29 ANN SAN ANT BREAS

[2]

Bianchi G, 2005, EJC SUPPL, V3, P78

[3]

Carpenter JT, 2005, J CLIN ONCOL S16, V23

[4] A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer [J].

Cobleigh, MA ;

Langmuir, VK ;

Sledge, GW ;

Miller, KD ;

Haney, L ;

Novotny, WF ;

Reimann, JD ;

Vassel, A .

SEMINARS IN ONCOLOGY, 2003, 30 (05) :117-124

[5]

CORTES J, 2005, J CLIN ONCOL S16, V23

[6]

CRESTA S, 2006, J CLIN ONCOL S18, V24

[7]

Geyer CE, 2006, J CLIN ONCOL, V24, p23S

[8] Trastuzumab in the treatment of breast cancer [J].

Hortobagyi, GN .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1734-1736

[9]

Hurwitz H, 2005, J CLIN ONCOL, V23, p195S

[10]

KAUR H, 2006, J CLIN ONCOL S18, V24

← 1 2 →